Anjarium Biosciences
Schlieren
About Anjarium Biosciences
Anjarium is focused on creating a new class of non-viral gene therapies to deliver more predictable, enduring, and inclusionary ways to tackle genetic diseases throughout a patient's lifetime. Combining deep domain expertise in synthetic and natural delivery systems, Anjarium is developing a novel class of bioinspired nanomedicine to address a range of genetic diseases, including those that necessitate very large gene delivery. Anjarium’s versatile platform systematically addresses key deficiencies of viral gene therapies in order to provide benefits to patients that have previously been out of reach.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $60.4M
- Funding stage: Early Stage Venture
- Last round: Series A (Sep 2021)
- Website: anjarium.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/anjarium-biosciences-65859 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.